Acceleris Capital

Power Roll Limited was established to develop and commercialise its highly innovative proprietary energy storage and energy generation technologies. Power Roll technologies exhibit a range of significant benefits and advantages over existing technologies such that it is likely that the technology can prove extremely disruptive across a wide range of applications and markets. Power Roll has a strong intellectual property portfolio, with 15 different patent families already established. These patent families are spread across all three technologies with five directly related to Energy Storage, nine related to Solar PV and one focusing on the nano-barrier technology.

Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).

Vertical Future is a technology company focused on building a better, more sustainable urban food production and supply system.

ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.

The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing need for new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance.

Apex Molecular is a synthetic chemistry company that is engaged in synthesis for the pharmaceutical, biotechnology, and applied chemical industries. They deliver laboratory-scale chemistry synthesis services for the life sciences and wider chemical sectors in a timely, dependable, and cost-effective manner.

The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing need for new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance.

InvestingZone Limited operates an online equity crowdfunding platform designed to connect early-stage and growth companies with experienced investors. Based in London and incorporated in 2012, the platform allows unlisted companies to raise funds while providing investors with essential rights and protections similar to those of venture capitalists. Users can build and manage investment portfolios, track performance, vote online, and engage directly with companies and other shareholders through a messaging service. InvestingZone aims to stimulate entrepreneurship by creating a secure environment for companies to manage shareholder relations, obtain votes, and network with stakeholders. The platform is supported by a team with a strong background in venture capital, offering access to innovative companies seeking investment in exchange for equity. As an appointed representative of a regulated fund manager, InvestingZone helps bridge the gap between mainstream investing and unlisted equities, catering to investors interested in diversifying their portfolios with high-risk, potentially high-return opportunities.

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.

EveryCloud's goal has always been to protect and support our customers. Since 2009, when myself and Graham O'Reilly started the company, we've obsessed over the best way to achieve this. We offer what we believe is the most responsive and versatile support in the industry alongside the most feature rich and secure technology. These two elements have allowed us to become a real leader in the market and in 2015 we were thrilled to become the Highest Rated Hosted Spam Filtering Vendor on Spiceworks.com (a community of 6 million IT Professionals), achieved through genuine reviews from our wonderful customers. Today we filter over 300 million emails a month for over 2,000 organisations. We have offices in the United Kingdom, United States and have staff across the globe. Our service is used in 13 different countries and along with our technology partner we have 5 data centres operating across our territories. Our customers experience expert guidance all the way through the journey from set up to renewal with dedicated account managers and support representatives.

The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing need for new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance.

Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).

ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.

Femeda is a UK based company focused on developing a range of technically ground breaking devices for female urinary incontinence. Femeda is established with the sole objective of developing and bringing to market the unique Pelviva device to treat female urinary incontinence. The company's research and development programme has been driven by core consumer needs to ensure the Pelviva product has been developed to make a difference to women’s lives. Femeda believes that Pelviva is a life changing technological breakthrough for weak pelvic floor muscles that cause bladder leaks. Femeda has been supported by a core group of investors who’s vision has supported an in-depth research and development programme leading to an imminent product launch in early 2018.

Microvisk Technologies is a UK based company developing Micro Electro Mechanical Sensors for the international medical market.